Quebrachitol: Global Status and Basic Research

Recently, there has been a renewed interest in the natural-products-inspired drugs. Quebrachitol (QCT) is one of naturally occurring optically active cyclitols that has now received considerable attention. Until the last decade, it came to be a starting point for the lead discovery. In this review, we had a discussion on the basic research of QCT, including its source, structure, properties, and the recent advances on its application. The biological activities and QCT-inspired leads that are potentially effective for treating human diseases were also discussed.

[1]  S C Johnson,et al.  Synthesis and evaluation of 3-modified 1D-myo-inositols as inhibitors and substrates of phosphatidylinositol synthase and inhibitors of myo-inositol uptake by cells. , 1993, Journal of medicinal chemistry.

[2]  Seiichiro Ogawa,et al.  Synthesis of acyclic and heterocyclic natural products utilizing cyclitols as novel chiral building blocks , 1997 .

[3]  P. Puigserver,et al.  Targeting hepatic glucose metabolism in the treatment of type 2 diabetes , 2016, Nature Reviews Drug Discovery.

[4]  Petra Schneider,et al.  Counting on natural products for drug design. , 2016, Nature chemistry.

[5]  R. Auten,et al.  Oxygen Toxicity and Reactive Oxygen Species: The Devil Is in the Details , 2009, Pediatric Research.

[6]  Wagner B. De Almeida,et al.  Synthesis of Mercaptobenzothiazole and Mercaptobenzimidazole Condensed with Inositol Derivatives , 2013 .

[7]  F. Koehn,et al.  The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.

[8]  B. Potter,et al.  Synthesis from quebrachitol of 1L-chiro-inositol 2,3,5-trisphosphate, an inhibitor of the enzymes of 1D-myo-inositol 1,4,5-trisphosphate metabolism , 1992 .

[9]  Jorge Cortes,et al.  Systems approaches and algorithms for discovery of combinatorial therapies. , 2009, Wiley interdisciplinary reviews. Systems biology and medicine.

[10]  Masahiro Akishita,et al.  Src kinase-mediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthase. , 2012, Biochemical and biophysical research communications.

[11]  F. Nan,et al.  A versatile approach to PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 from L-(-)-Quebrachitol , 2000 .

[12]  Huicong Wang,et al.  Methyl-inositol, γ-aminobutyric acid and other health benefit compounds in the aril of litchi , 2016, International journal of food sciences and nutrition.

[13]  Angel Lanas.  Improving on Our Goal to Reduce NSAID-Induced GI Complications: A Challenging Task? , 2008, The American Journal of Gastroenterology.

[14]  P. Tyler,et al.  New syntheses of 1D- and 1L-1,2-anhydro-myo-inositol and assessment of their glycosidase inhibitory activities. , 2000, Carbohydrate research.

[15]  B. Potter,et al.  Synthesis of L-chiro-inositol 1,4,6-trisphosphorothioate, a potent and selective inhibitor of myo-inositol 1,4,5-trisphosphate 5-phosphatase , 1992 .

[16]  Shana J Sturla,et al.  Deoxygenated phosphorothioate inositol phosphate analogs: synthesis, phosphatase stability, and binding affinity. , 2008, Bioorganic & Medicinal Chemistry.

[17]  D. Kingston,et al.  Proposed active constituents of Dipladenia martiana , 2001, Phytotherapy research : PTR.

[18]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[19]  B V Potter,et al.  Synthesis of 1L-chiro-inositol 2,3,5-trisphosphorothioate, the first partial agonist at the platelet myo-inositol 1,4,5-trisphosphate receptor. , 1994, Bioorganic & medicinal chemistry.

[20]  G. Tang,et al.  Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers , 2013, British Journal of Cancer.

[21]  Luis Rodrigo,et al.  A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use , 2005, The American Journal of Gastroenterology.

[22]  S. R. Nahorski,et al.  1D-myo-inositol 1,4,5-trisphosphate and 1D-myo-inositol 1,3,4,5-tetrakisphosphate analogues modified at C-3; synthesis of 1D-3-C-(trifluoromethyl)-myo-inositol 1,4,5-trisphosphate and 1L-chiro-insitol 1,2,3,5-tetrakisphosphate from L-quebrachitol , 1994 .

[23]  Sylvia M Baars,et al.  Improved synthesis of dicyclohexylidene protected quebrachitol and its use in the synthesis of L-chiro-inositol derivatives. , 2006, Carbohydrate research.

[24]  Seiichiro Ogawa,et al.  TOTAL SYNTHESIS OF ACANTHACEREBROSIDE A AND ASTROCEREBROSIDE A VIA A CHIRAL EPOXIDE INTERMEDIATE DERIVED FROM L-QUEBRACHITOL , 1998 .

[25]  Khozirah Shaari,et al.  Inhibitory Effects of Phylligenin and Quebrachitol Isolated from Mitrephora vulpina on Platelet Activating Factor Receptor Binding and Platelet Aggregation , 2010, Molecules.

[26]  Robert H. Michell,et al.  Inositol derivatives: evolution and functions , 2008, Nature Reviews Molecular Cell Biology.

[27]  R. Lemoine,et al.  Cloning and characterization of a new polyol transporter (HbPLT2) in Hevea brasiliensis. , 2010, Plant & cell physiology.

[28]  G. Powis,et al.  Synthesis of D-3-deoxy-3-phosphonomethyl-myo-inositol and its dimethyl ester - compounds of use in studying the ptdins-3′-kinase signalling pathway , 1993 .

[29]  Alan L Harvey,et al.  Natural products in drug discovery. , 2008, Drug discovery today.

[30]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[31]  Djaja D. Soejarto,et al.  Dereplication of Saccharide and Polyol Constituents of Candidate Sweet‐tasting Plants: Isolation of the Sesquiterpene Glycoside Mukurozioside IIb as a Sweet Principle of Sapindus rarak , 1997 .

[32]  B. Decorte,et al.  Underexplored Opportunities for Natural Products in Drug Discovery. , 2016, Journal of medicinal chemistry.

[33]  Shoichiro Ozaki,et al.  Total Synthesis of Cyclophellitol from L-Quebrachitol , 1991 .

[34]  B. Potter,et al.  Total synthesis from L-quebrachitol of the D-myo-inositol 1,4,5-trisphosphate analogue, L-chiro-inositol 2,3,5-trisphosphate, a potent inositol 1,4,5-trisphosphate 5-phosphatase and 3-kinase inhibitor , 1991 .

[35]  Alexander Kamb,et al.  Why is cancer drug discovery so difficult? , 2007, Nature Reviews Drug Discovery.

[36]  Seiichiro Ogawa,et al.  Stereoselective conversion of l-quebrachitol into a novel hydroxylated caprolactam: Total synthesis of bengamide B , 1994 .

[37]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[38]  R D Lawrence,et al.  An investigation of quebrachitol as a sweetening agent for diabetics. , 1933, The Biochemical journal.

[39]  Cathryn M. Lewis,et al.  Psychoneuroendocrinology , 1979, Pharmacology Biochemistry and Behavior.

[40]  Seiichiro Ogawa,et al.  Utilisation of L-quebrachitol in natural product synthesis. Total synthesis and absolute configuration of (–)-oudemansin X , 1993 .

[41]  G. Superti-Furga,et al.  Rediscovering the sweet spot in drug discovery. , 2003, Drug discovery today.

[42]  Nam Deuk Kim,et al.  Active components from Artemisia iwayomogi displaying ONOO− scavenging activity , 2004, Phytotherapy research : PTR.

[43]  P. Zimmet,et al.  Diabetes mellitus statistics on prevalence and mortality: facts and fallacies , 2016, Nature Reviews Endocrinology.

[44]  D. Barton,et al.  Total synthesis of (–)-ovalicin and analogues from L-quebrachitol , 1995 .

[45]  Cynthia L. Jordan,et al.  Membrane androgen receptors may mediate androgen reinforcement , 2010, Psychoneuroendocrinology.

[46]  J. Choi,et al.  Chlorogenic acid, an antioxidant principle from the aerial parts ofArtemisia iwayomogi that acts on 1,1-diphenyl-2-picrylhydrazyl radical , 1997, Archives of pharmacal research.

[47]  Hélio F. Dos Santos,et al.  Synthesis and theoretical study of azido and amino inositol derivatives from l-quebrachitol , 2001 .

[48]  Eila Järvenpää,et al.  Inositols and methylinositols in sea buckthorn (Hippophaë rhamnoides) berries. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[49]  Smain Amira,et al.  Protective effect of mannitol, glucose-fructose-sucrose-maltose mixture, and natural honey hyperosmolar solutions against ethanol-induced gastric mucosal damage in rats. , 2001, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[50]  Popp,et al.  Cyclitols as cryoprotectants for spinach and chickpea thylakoids. , 2000, Environmental and experimental botany.

[51]  T L G Lemos,et al.  Quebrachitol (2-O-methyl-L-inositol) attenuates 6-hydroxydopamine-induced cytotoxicity in rat fetal mesencephalic cell cultures. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[52]  P. H. Hewitt,et al.  Quebrachitol: A phagostimulant for the larvae of the moth, Serrodes partita , 1969 .

[53]  Roger Adams,et al.  Isolation of Cannabinol, Cannabidiol and Quebrachitol from Red Oil of Minnesota Wild Hemp , 1940 .

[54]  F. Santos,et al.  Quebrachitol-induced gastroprotection against acute gastric lesions: role of prostaglandins, nitric oxide and K+ ATP channels. , 2008, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[55]  K. Chow,et al.  Effects of Platelet Activating Factor, Butyrate and Interleukin-6 on Cyclooxygenase-2 Expression in Human Esophageal Cancer Cells , 2002, Scandinavian journal of gastroenterology.

[56]  入江 正浩,et al.  Bull. Chem. Soc. Jpn. への投稿のすすめ , 2011 .

[57]  Michael K. Dowd,et al.  THE CRYSTAL STRUCTURES OF d-PINITOL AND l-QUEBRACHITOL BY LOW-TEMPERATURE X-RAY DIFFRACTION , 2002 .

[58]  Seiichiro Ogawa,et al.  Total synthesis of (−)-PA-48153C (pironetin) utilising l-quebrachitol as a chiral building block , 1997 .

[59]  P. Dennis,et al.  Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. , 2003, Journal of the American Chemical Society.

[60]  Kentaro Yamaguchi,et al.  Synthesis of a novel crown ether derived from chiro-inositol and its catalytic activity on the asymmetric Michael addition. , 2003, Chemical communications.

[61]  Keh-Feng Huang,et al.  Crystal Structure of L-Quebrachitol , 1994 .

[62]  C. Rossini,et al.  First record of L-quebrachitol in Allophylus edulis (Sapindaceae). , 2008, Carbohydrate research.

[63]  M. Popp,et al.  Functional role of polyhydroxy compounds on protein structure and thermal stability studied by circular dichroism spectroscopy. , 2008, Plant physiology and biochemistry : PPB.

[64]  Heikki Kallio,et al.  Effects of sea buckthorn (Hippophaë rhamnoides) juice and L-quebrachitol on type 2 diabetes mellitus in db/db mice , 2015 .

[65]  D. Newman,et al.  Natural Products as Sources of New Drugs from 1981 to 2014. , 2016, Journal of natural products.

[66]  Liron Levy,et al.  Trends in the development of chiral drugs. , 2004, Drug discovery today.

[67]  Seiichiro Ogawa,et al.  Formal total syntheses of (–)-isoavenaciolide and (–)-ethisolide from L-quebrachitol , 1992 .

[68]  S Russo,et al.  PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. , 2000, The American journal of pathology.

[69]  James J. Kiddle.  Quebrachitol: A versatile building block in the construction of naturally occurring bioactive materials , 1995 .